Hiccup For Evotec As Bayer Pulls Plug On Chronic Cough Drug
German Major Discontinuing Development Of Eliapixant
With the future of eliapixant in doubt, Shinogi's sivopixant struggling and a recent FDA rejection for Merck & Co's chronic cough drug gefapixant, Bellus Health's BLU-5937 looks to have emerged as a best-in-class agent in the P2X3 space.
You may also be interested in...
GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.